Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study.

Huang F, Voelk C, Trampisch M, Rowland L, Schultz A, Sabo JP.

Basic Clin Pharmacol Toxicol. 2018 Jul;123(1):84-93. doi: 10.1111/bcpt.12980. Epub 2018 Mar 30.

PMID:
29427400
2.

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.

Yong CL, Gathe JC, Knecht G, Orrell C, Mallolas J, Podzamczer D, Trottier B, Zhang W, Sabo JP, Vinisko R, Drulak M, Quinson AM.

HIV Clin Trials. 2017 Nov-Dec;18(5-6):189-195. doi: 10.1080/15284336.2017.1386811.

PMID:
29210627
3.

Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes.

Sane RS, Ramsden D, Sabo JP, Cooper C, Rowland L, Ting N, Whitcher-Johnstone A, Tweedie DJ.

Drug Metab Dispos. 2016 Mar;44(3):466-75. doi: 10.1124/dmd.115.066985. Epub 2015 Dec 18.

4.

Nevirapine extended-release formulation tablets in HIV-1-infected children--long-term follow-up.

Anabwani G, Königs C, Giaquinto C, Aslanyan S, Sabo JP, Morrow JS, Feiterna-Sperling C.

Clin Infect Dis. 2015 Aug 1;61(3):476-9. doi: 10.1093/cid/civ340. Epub 2015 Apr 26.

PMID:
25917636
5.

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.

Zeuzem S, Soriano V, Asselah T, Gane EJ, Bronowicki JP, Angus P, Lohse AW, Stickel F, Müllhaupt B, Roberts S, Schuchmann M, Manns M, Bourlière M, Buti M, Stern JO, Gallivan JP, Voss F, Sabo JP, Böcher W, Mensa FJ; SOUND-C2 Study Group.

Antimicrob Agents Chemother. 2015 Feb;59(2):1282-91. doi: 10.1128/AAC.04383-14. Epub 2014 Dec 15.

6.

Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation.

Sabo JP, Kort J, Ballow C, Kashuba AD, Haschke M, Battegay M, Girlich B, Ting N, Lang B, Zhang W, Cooper C, O'Brien D, Seibert E, Chan TS, Tweedie D, Li Y.

J Clin Pharmacol. 2015 Apr;55(4):467-77. doi: 10.1002/jcph.436. Epub 2015 Jan 14.

PMID:
25449227
7.
8.

Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor.

Chen LZ, Sabo JP, Philip E, Rowland L, Mao Y, Latli B, Ramsden D, Mandarino DA, Sane RS.

Antimicrob Agents Chemother. 2015 Jan;59(1):25-37. doi: 10.1128/AAC.03861-14. Epub 2014 Oct 13.

9.

Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.

Sabo JP, Kort J, Ballow C, Haschke M, Battegay M, Fuhr R, Girlich B, Schobelock M, Feifel U, Lang B, Li Y, Elgadi M.

Clin Infect Dis. 2014 Nov 15;59(10):1420-8. doi: 10.1093/cid/ciu616. Epub 2014 Aug 4.

PMID:
25091302
10.

Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.

Giaquinto C, Anabwani G, Feiterna-Sperling C, Nuttall J, Mompati K, Königs C, Mensa FJ, Sabo JP, Yong CL, MacGregor TR, Nguyen T, Quinson AM.

Pediatr Infect Dis J. 2014 Jul;33(7):e173-9. doi: 10.1097/INF.0000000000000241.

PMID:
24378938
11.

Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers.

Kort JJ, Aslanyan S, Scherer J, Sabo JP, Kohlbrenner V, Robinson P.

Curr HIV Res. 2011 Jun;9(4):237-46. doi: 10.2174/157016211796320306.

12.

Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers.

Garraffo R, Lavrut T, Ferrando S, Durant J, Rouyrre N, MacGregor TR, Sabo JP, Dellamonica P.

J Clin Pharmacol. 2011 Jul;51(7):1071-8. doi: 10.1177/0091270010379808. Epub 2011 Jan 5.

PMID:
21209236
13.

Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.

Sabo JP, Cong XJ, Kraft MF, Wallace L, Castles MA, Mauss S, MacGregor TR.

Eur J Clin Pharmacol. 2011 Mar;67(3):277-81. doi: 10.1007/s00228-010-0907-1. Epub 2010 Oct 12.

PMID:
20963404
14.

Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.

Goebel FD, MacGregor TR, Sabo JP, Castles M, Johnson PA, Legg D, McCallister S.

HIV Clin Trials. 2010 Jan-Feb;11(1):28-38. doi: 10.1310/hct1101-28.

PMID:
20400409
15.

A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.

Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD.

Clin Pharmacol Ther. 2010 Jun;87(6):735-42. doi: 10.1038/clpt.2009.253. Epub 2010 Feb 10.

16.

Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.

Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH.

Drug Alcohol Depend. 2009 Dec 1;105(3):234-9. doi: 10.1016/j.drugalcdep.2009.07.007. Epub 2009 Sep 1.

17.

Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.

la Porte CJ, Sabo JP, Béïque L, Cameron DW.

Antimicrob Agents Chemother. 2009 Nov;53(11):4840-4. doi: 10.1128/AAC.00462-09. Epub 2009 Aug 31.

18.

Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.

Pham PA, la Porte CJ, Lee LS, van Heeswijk R, Sabo JP, Elgadi MM, Piliero PJ, Barditch-Crovo P, Fuchs E, Flexner C, Cameron DW.

Antimicrob Agents Chemother. 2009 Oct;53(10):4385-92. doi: 10.1128/AAC.00449-09. Epub 2009 Aug 10.

19.

Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers.

la Porte CJ, Sabo JP, Elgadi M, Cameron DW.

Antimicrob Agents Chemother. 2009 Jan;53(1):162-73. doi: 10.1128/AAC.00534-08. Epub 2008 Nov 17.

20.

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.

Raffi F, Battegay M, Rusconi S, Opravil M, Blick G, Steigbigel RT, Kraft M, Neubacher D, Sabo JP.

AIDS. 2007 Sep 12;21(14):1977-80. Erratum in: AIDS. 2008 Aug 20;22(13):i.

21.

Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.

Chen L, Sabo JP, Philip E, Mao Y, Norris SH, MacGregor TR, Wruck JM, Garfinkel S, Castles M, Brinkman A, Valdez H.

Antimicrob Agents Chemother. 2007 Jul;51(7):2436-44. Epub 2007 May 7.

22.

Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.

Mukwaya G, MacGregor T, Hoelscher D, Heming T, Legg D, Kavanaugh K, Johnson P, Sabo JP, McCallister S.

Antimicrob Agents Chemother. 2005 Dec;49(12):4903-10.

23.

Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.

MacGregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, McCallister S.

HIV Clin Trials. 2004 Nov-Dec;5(6):371-82.

PMID:
15682350
24.

Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.

Sabo JP, Lamson MJ, Leitz G, Yong CL, MacGregor TR.

AAPS PharmSci. 2000;2(1):E1.

25.

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers.

Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, Cappola M, Robinson P.

Biopharm Drug Dispos. 1999 Sep;20(6):285-91.

PMID:
10701699
26.

Isotype choice for chimeric antibodies affects binding properties.

Morelock MM, Rothlein R, Bright SM, Robinson MK, Graham ET, Sabo JP, Owens R, King DJ, Norris SH, Scher DS, et al.

J Biol Chem. 1994 Apr 29;269(17):13048-55.

27.

BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.

Richman D, Rosenthal AS, Skoog M, Eckner RJ, Chou TC, Sabo JP, Merluzzi VJ.

Antimicrob Agents Chemother. 1991 Feb;35(2):305-8.

28.

Effects of the Clara cell toxin, 4-ipomeanol, on pulmonary function in rats.

Sabo JP, Kimmel EC, Diamond L.

J Appl Physiol Respir Environ Exerc Physiol. 1983 Feb;54(2):337-44.

PMID:
6833030
29.

Acute toxicity of latex microspheres.

Yokel RA, Sabo JP, Simmons GH, DeLuca PP.

Toxicol Lett. 1981 Oct;9(2):165-70.

PMID:
7302990
30.

The effect of selected drugs on first-stage radioemesis in beagle dogs.

Gralla EJ, Sabo JP, Hayden DW, Yochmowitz MG, Mattsson JL.

Radiat Res. 1979 May;78(2):286-95. No abstract available.

PMID:
221957

Supplemental Content

Support Center